The newly developed antibody shows a significant reduction in amyloid pathology in mice with Alzheimer’s disease. The TREM2 transmembrane receptor expressed in cells of the myeloid lineage plays a crucial role in Alzheimer’s disease.
During the extensive research, a team of scientists identified the potential treatment with a newly developed antibody. The researchers identified the agonistic antibody can potentially reduce the amyloid pathology of Alzheimer’s disease thereby confirming a potential treatment for the disease.
Zhiqiang An, the lead author of the study and a scientist from the University of Texas, United States, said “Antibody-based therapy is a viable drug modality for the treatment of Alzheimer’s disease. One of the major areas of focus at the Texas Therapeutics Institute is developing technologies to deliver antibody-based therapies across the blood-brain barrier for the potential treatment of the disease.”
During the study, the researchers discovered that a tetra-variable domain antibody, targeting the triggering receptor expressed on myeloid 2 (TREM2), reduced amyloid strain, eased neuron damage, and alleviated cognitive decline in mice with Alzheimer’s disease.
